Compagnie Lombard Odier SCmA Sells 29,897 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Compagnie Lombard Odier SCmA trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 18.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 132,971 shares of the medical research company's stock after selling 29,897 shares during the period. Compagnie Lombard Odier SCmA owned about 0.07% of IQVIA worth $26,130,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in IQV. Exchange Traded Concepts LLC lifted its stake in shares of IQVIA by 2.3% in the third quarter. Exchange Traded Concepts LLC now owns 4,388 shares of the medical research company's stock valued at $1,040,000 after buying an additional 98 shares in the last quarter. Creative Planning lifted its stake in shares of IQVIA by 17.8% in the third quarter. Creative Planning now owns 21,013 shares of the medical research company's stock valued at $4,980,000 after buying an additional 3,176 shares in the last quarter. Swedbank AB lifted its stake in shares of IQVIA by 0.9% in the third quarter. Swedbank AB now owns 91,489 shares of the medical research company's stock valued at $21,680,000 after buying an additional 786 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in shares of IQVIA by 20.4% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 5,719 shares of the medical research company's stock valued at $1,355,000 after buying an additional 968 shares in the last quarter. Finally, nVerses Capital LLC bought a new position in shares of IQVIA in the third quarter valued at $379,000. 89.62% of the stock is owned by institutional investors.

Insider Activity

In related news, Director John G. Danhakl bought 1,275 shares of the company's stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently commented on IQV shares. TD Cowen lowered their target price on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a report on Friday, November 1st. Morgan Stanley increased their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. UBS Group lowered their target price on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday. Finally, Truist Financial reiterated a "buy" rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $251.22.

IQVIA Price Performance

Shares of IQV stock traded down $0.17 during trading hours on Tuesday, reaching $193.27. The stock had a trading volume of 1,539,795 shares, compared to its average volume of 1,403,368. The stock's fifty day simple moving average is $200.15 and its 200 day simple moving average is $217.43. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The firm has a market capitalization of $35.08 billion, a PE ratio of 25.77, a PEG ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.